64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
A phase 1/2 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.
Overview
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) is a phase 1/2 interventional study registered as NCT04868604 by Clarity Pharmaceuticals Ltd, with 54 participants planned, started 2021-08-11 and due to reach its primary completion in 2026-09. Interventions recorded: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA.
Similar pages
not linked directly; found by shared links- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- TrialCopper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Shares Copper-64, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- TrialSafety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
Shares Copper-64, Prostate cancer and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.